Auzou P, Ozsancak C, Jan M, Léonardon S, Ménard J F, Gaillard M J, Eustache F, Hannequin D
Service de Neurophysiologie, CHU, Rouen et Inserm U320, Caen.
Rev Neurol (Paris). 1998 Jul;154(6-7):523-30.
We adapted in French the Frenchay Dysarthria Assessment (FDA) developed by P. Enderby in 1983. This tool quantitatively evaluates the organs involved in speech and provides a measurement of intelligibility. Productions of normal subjects were analyzed. Reproductibility of data (correlation and interobserver concordance) was high in 18 dysarthric patients. A study performed in 100 dysarthric patients corresponding to 4 types of dysarthria (spastic, ataxic, hypokinetic and mixte) showed that dysarthria resulted from a global impairment of organs implied in speech, rather than one specific organ. The reduction in the intelligibility score was related to organ impairment.
我们将P. 恩德比于1983年开发的法国ay构音障碍评估（FDA）改编成了法语版本。该工具对参与言语的器官进行定量评估，并提供可懂度的测量。分析了正常受试者的发音情况。在18名构音障碍患者中，数据的可重复性（相关性和观察者间一致性）很高。对100名对应4种构音障碍类型（痉挛型、共济失调型、运动减少型和混合型）的构音障碍患者进行的一项研究表明，构音障碍是由言语中涉及的器官整体受损引起的，而非某个特定器官。可懂度得分的降低与器官损伤有关。
